All In Biotech

Drug Trial Radar · NCT06190093

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Jan 24, 2024

Primary completion

Nov 7, 2024

Study completion Dec 5, 2024

Sponsor

Lead sponsor
Outlook Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.

Conditions

  • Neovascular Age-related Macular Degeneration
  • Age-Related Macular Degeneration
  • Wet Macular Degeneration

Interventions

  • bevacizumabBiological

    1.25 mg, intravitreal injection

  • ranibizumabBiological

    0.5mg, intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8Time frame: Baseline, 8 weeks

Locations

61 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Arcadia, California

  • Clinical Site

    Bakersfield, California

  • Clinical Site

    Beverly Hills, California

  • Clinical Site

    Huntington Beach, California

  • Clinical Site

    Laguna Hills, California

  • Clinical Site

    Long Beach, California

  • Clinical Site

    Modesto, California

  • Clinical Site

    Oakland, California

  • Clinical Site

    Pasadena, California

  • Clinical Site

    Poway, California

  • Clinical Site

    Sacramento, California

  • Clinical Site

    Colorado Springs, Colorado

  • Clinical Site

    Lakewood, Colorado

  • Clinical Site

    Waterford, Connecticut

  • Clinical Site

    Coral Springs, Florida

  • Clinical Site

    Fort Lauderdale, Florida

  • Clinical Site

    Jacksonville, Florida

  • Clinical Site

    Orlando, Florida

  • Clinical Site

    Stuart, Florida

  • Clinical Site

    Oak Forest, Illinois

  • Clinical Site

    Oak Park, Illinois

  • Clinical Site

    Carmel, Indiana

  • Clinical Site

    Lenexa, Kansas

  • Clinical Site

    Lexington, Kentucky

  • Clinical Site

    Hagerstown, Maryland

  • Clinical Site

    Edina, Minnesota

  • Clinical Site

    Saint Louis Park, Minnesota

  • Clinical Site

    Jackson, Mississippi

  • Clinical Site

    Teaneck, New Jersey

  • Clinical Site

    Albuquerque, New Mexico

  • Clinical Site

    Liverpool, New York

  • Clinical Site

    Oceanside, New York

  • Clinical Site

    Rochester, New York

  • Clinical Site

    Westbury, New York

  • Clinical Site

    Asheville, North Carolina

  • Clinical Site

    Hickory, North Carolina

  • Clinical Site

    Wake Forest, North Carolina

  • Clinical Site

    Winston-Salem, North Carolina

  • Clinical Site

    Edmond, Oklahoma

  • Clinical Site

    Charleston, South Carolina

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.